Breaks Categories: News

WednesdayApr 02, 2025 9:37 am

NetworkNewsBreaks – Brera Holdings PLC (NASDAQ: BREA) Regains Nasdaq Compliance After Holding Annual Meeting

Brera Holdings (NASDAQ: BREA), an Ireland-based company focused on expanding a global portfolio of men's and women's sports clubs through a multi-club ownership model, announced it has regained compliance with Nasdaq Listing Rule 5620(a) following its annual meeting on March 28. Nasdaq had issued a non-compliance notice on Feb. 3, but the matter is now officially closed.  To view the full press release, visit https://nnw.fm/XaB5l  About Brera Holdings PLC  Brera Holdings PLC is focused on expanding its social impact football (soccer) business by developing a global portfolio of emerging football and other sports clubs, which will provide increased opportunities to…

Continue Reading

TuesdayApr 01, 2025 2:49 pm

NetworkNewsBreaks – Alt Pro Expo Set to Light Up Miami, Showcase Counterculture Innovation

The Alternative Products Expo (“Alt Pro Expo”), a production of ZJ Events, is returning to Miami at the Miami Expo 2025. The event is set to take the stage at the dynamic and innovative Mana Wynwood Convention Center from April 3-5. “The Alternative Products Expo – Miami Expo is the leading B2B-only event in the counterculture industry and is a hub for driving market awareness, showcasing innovation, and building collaborative professional networks,” said Director of Partnerships Sebastian Carmona. “As the industry flagship expo for smoke shop professionals, we're thrilled to return to Miami—a city with deep historical and cultural ties…

Continue Reading

TuesdayApr 01, 2025 1:31 pm

NetworkNewsBreaks – Fifty 1 Labs Inc. (FITY), Genetic Networks Set to Push the Boundaries of Biotechnology 

Fifty 1 Labs (OTC: FITY), a forward-thinking leader in biotechnology and health innovation, today announced a groundbreaking achievement by its recently acquired subsidiary, Genetic Networks, in space-based biotechnology. The milestone stems from over a decade of space-based functional genomics from Dr. Corey Nislow's laboratory, with the work highlighting the pivotal role of functional genomics in diverse aspects of human health and wellness. According to Dr. Nislow, the experiment findings have the potential to unlock new pathways for pharmaceutical development and human health in space exploration.  “We are thrilled to celebrate this achievement by Genetic Networks and to have Dr. Corey…

Continue Reading

TuesdayApr 01, 2025 11:36 am

NetworkNewsBreaks – Sekur Private Data Ltd. (CSE: SKUR) (OTCQX: SWISF) (FSE: GDT0) Launches CA$1.4 Million Private Placement to Fuel U.S. Growth 

  Sekur Private Data (CSE: SKUR) (OTCQB: SWISF) (FSE: GDT0), a Swiss-hosted cybersecurity and privacy communications provider, announced a non-brokered private placement to raise up to CA$1.4 million (US$1 million). The offering includes up to 40,000,000 units priced at CA$0.035 each, with each unit consisting of one common share and one full warrant exercisable at CA$0.05 for 24 months. Proceeds will support U.S. marketing efforts for Sekur’s privacy solutions and general working capital needs.  To view the full press release, visit https://nnw.fm/6fwnQ  About Sekur Private Data Ltd.  Sekur Private Data is a cybersecurity and internet privacy provider of Swiss-hosted solutions for…

Continue Reading

TuesdayApr 01, 2025 11:30 am

NetworkNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Surpasses 800 Advertisers, Maintains 243% CAGR Amid Rapid Expansion

Thumzup (NASDAQ: TZUP), a rising AdTech player in social media branding and programmatic marketing, announced it has exceeded 800 advertisers on its platform, with expectations to cross 1,000 by mid Q2 2025. The company reported a 243% compound annual growth rate, fueled by strategic expansion into South Florida, Miami, and Greater Salt Lake City. Thumzup’s platform integrates with major social networks, including Instagram Reels and X, reaching over 535 million users monthly. To view the full press release, visit https://nnw.fm/O50DS About Thumzup® Thumzup Media Corporation is democratizing the multi-billion dollar social media branding and marketing industry. Its flagship product, the…

Continue Reading

TuesdayApr 01, 2025 11:11 am

NetworkNewsBreaks – Nightfood Holdings Inc. (OTCQB: NGTF) Acquires Skytech to Expand AI Robotics in Hospitality Sector 

Nightfood Holdings (OTCQB: NGTF), an innovator in hospitality automation, has acquired Skytech Automated Solutions, Inc., a leader in AI-driven service technologies for hotels. This strategic move follows Nightfood’s recent acquisition of Carryout Supplies and enhances its Robotics-as-a-Service (RaaS) offerings. Skytech’s Laundry Helper robot, already in use at multiple hotel properties, will now be integrated into Nightfood’s broader automation platform to improve operational efficiency and guest experience. The combined capabilities are expected to boost market reach, recurring revenue, and operational scalability.  To view the full press release, visit https://nnw.fm/YSPBT  About Nightfood Holdings Inc.  Nightfood is a forward-thinking holding company dedicated to…

Continue Reading

TuesdayApr 01, 2025 10:34 am

NetworkNewsBreaks – XTI Aerospace Inc. (NASDAQ: XTIA) Closes $4 Million Public Offering to Repay Debt and Fund Operations 

XTI Aerospace (NASDAQ: XTIA), a developer of vertical takeoff and landing (“VTOL”) aircraft, has closed a public offering of 2,941,200 shares of common stock (or pre-funded warrants) and an equal number of accompanying warrants at a combined offering price of $1.36 per unit. The five-year warrants are immediately exercisable at the same price. Gross proceeds totaled approximately $4 million before expenses, which the company will use for general working capital and to repay outstanding secured promissory notes.  To view the full article, visit https://nnw.fm/mklVh  About XTI Aerospace, Inc.  XTI Aerospace ( XTIAerospace.com ) (Nasdaq: XTIA) is the parent company of XTI Aircraft…

Continue Reading

TuesdayApr 01, 2025 10:00 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing its primary endpoint in a glioblastoma multiforme (GBM) trial, the drug demonstrated safety and comparable efficacy, guiding future analysis. The company is shifting focus to TPI 287, a candidate with orphan drug designation and prior clinical data. With $6.5 million in cash at year-end and an additional $9.9 million raised post-period, CNS expects funding to last through Q1 2026. To view the full press release,…

Continue Reading

TuesdayApr 01, 2025 9:50 am

NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Jones Healthcare and Technology Innovation Conference on April 9

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company advancing treatments for neurodegenerative diseases like ALS and MS, will present at the Jones Healthcare and Technology Innovation Conference on April 9, 2025, at 11:30 a.m. PT. The event will be held at the Venetian Resort in Las Vegas and include 1x1 investor meetings. A webcast of the presentation will be available via the events section of Clene’s website. To view the full press release, visit https://nnw.fm/VRmfe About Clene Inc. Clene (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving…

Continue Reading

TuesdayApr 01, 2025 9:40 am

NetworkNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $3.9 Million Offering to Advance Immunotherapy Programs

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company developing targeted immunotherapies, closed its previously announced registered direct offering and concurrent private placement with a single institutional investor, raising approximately $3.9 million in gross proceeds. The offering included 3,325,000 shares of common stock and pre-funded warrants for 2,728,000 shares, along with Series G warrants for 6,053,000 shares. Proceeds will support working capital and advance Calidi’s clinical and preclinical cancer therapy programs. To view the full press release, visit: https://nnw.fm/nr4cW About Calidi Biotherapeutics Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem…

Continue Reading